7月12日，全球疫苗免疫联盟宣布，中国国药集团和科兴生物已与“新冠肺炎疫苗实施计划”签署合作协议，两家企业将在今年10月前向该计划提供1.1亿剂疫苗，用于发展中国家疫情防控。目前，中国已向全球提供5亿剂新冠疫苗和原液，相当于当前全球新冠疫苗总产量的六分之一。The Gavi Alliance on Monday said it had signed advance purchase agreements with Sinopharm and Sinovac to make 110 million vaccine doses immediately available to participants of the COVAX Facility starting this month.From July to October this year, 60 million doses of the Sinopharm vaccine will be made available, while 50 million doses of the Sinovac vaccine will be made available from July to October, according to a statement by Gavi.The agreements come at a time when the Delta variant is posing a rising risk to health systems.China has provided 500 million doses of COVID-19 vaccines to more than 100 countries and international organizations, equaling one-sixth of the current global COVID-19 vaccine production.5月11日，北京大兴，北京科兴中维生物技术有限公司生产车间内，工作人员在对疫苗进行包装称重
当地时间7月12日，世卫组织首席科学家苏米娅·斯瓦米纳坦在例行发布会上表示，世卫组织很高兴得知两款中国疫苗进入“新冠肺炎疫苗实施计划”疫苗库。全球疫苗免疫联盟（GAVI）12日发布新闻公报，宣布已同中国国药集团和科兴公司分别签署了预购协议，这意味着国药疫苗和科兴疫苗进入“新冠肺炎疫苗实施计划”（COVAX）疫苗库，并可从7月开始向COVAX供应疫苗以用于发展中国家的新冠疫情防控。全球疫苗免疫联盟首席执行官塞斯·伯克利在公报中说：“我欢迎今天的协议，这使得COVAX参与方可以立即获得疫苗。”WHO pays great thanks to Sinopharm and Sinovac for the COVAX vaccine plan.Gavi CEO Seth Berkley: "I welcome today's agreements, which will make doses immediately available to COVAX participants."
Netizens appraised China as a highly responsible country for the whole world.